Discipline of Microbiology, Institute of Biological and Natural Sciences, Federal University of Triângulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.
Laboratory of Green and Medicinal Chemistry, Department of Chemistry and Environmental Sciences, Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University (UNESP), São José do Rio Preto, São Paulo, Brazil.
J Appl Microbiol. 2019 Nov;127(5):1362-1372. doi: 10.1111/jam.14381. Epub 2019 Aug 14.
The increase in the number of fungal infections worldwide, coupled with the limitations of current antifungal chemotherapy, demand the development of safe and effective new antifungals. Here, we presented the synthesis of a novel acridone (M14) and its antifungal properties against Candida and dermatophytes species.
A series of 17 acridones was designed, synthesized and tested for its antifungal activity. The minimum inhibitory concentration (MIC) was determined by the broth microdilution method. Only the acridone M14 showed growth-inhibitory activity against reference strains and clinical isolates of Candida and dermatophytes, with MIC range of 7·81-31·25 µg ml . Moreover, M14 exhibited fungicidal activity and prevented biofilm formation by C. albicans as well as reduced the viability of preformed biofilms, even at sub-MICs. The confocal laser scanning microscopy analysis revealed that C. albicans hyphal growth was completely inhibited in the presence of M14. Similarly, there was a severe inhibition on hyphal growth of Trichophyton rubrum. We also found that M14 has relatively low toxicity to human fibroblasts.
The new acridone M14 has antifungal properties against Candida spp. and dermatophytes, and antibiofilm activity against C. albicans. In addition, M14 is relatively selective to fungal cells compared to human normal cells.
Because of its in vitro antifungal activity, anti-Candida biofilm effect and moderate cytotoxicity towards normal human cell, M14 may serve as a valuable lead compound to develop a new antifungal agent.
随着世界各地真菌感染数量的增加,以及当前抗真菌化疗的局限性,我们需要开发安全有效的新型抗真菌药物。在这里,我们介绍了一种新型吖啶酮(M14)的合成及其对念珠菌和皮肤真菌的抗真菌特性。
设计、合成了一系列 17 种吖啶酮,并对其抗真菌活性进行了测试。采用肉汤微量稀释法测定最低抑菌浓度(MIC)。只有吖啶酮 M14 对参考株和临床分离的念珠菌和皮肤真菌表现出生长抑制活性,MIC 范围为 7.81-31.25 μg/ml。此外,M14 表现出杀菌活性,可防止白色念珠菌生物膜的形成,并降低亚 MIC 浓度下已形成生物膜的活力。共聚焦激光扫描显微镜分析显示,M14 的存在完全抑制了白色念珠菌的菌丝生长。同样,对红色毛癣菌的菌丝生长也有严重的抑制作用。我们还发现 M14 对人成纤维细胞的毒性相对较低。
新型吖啶酮 M14 对念珠菌属和皮肤真菌具有抗真菌作用,对白色念珠菌具有抗生物膜活性。此外,与正常人类细胞相比,M14 对真菌细胞具有相对选择性。
由于其体外抗真菌活性、抗白色念珠菌生物膜作用和对正常人类细胞的中等细胞毒性,M14 可能成为开发新型抗真菌药物的有价值的先导化合物。